Pazopanib in metastatic multiply treated progressive gastrointestinal stromal tumors: feasible and efficacious

BACKGROUND: A median progression free survival (PFS) of 18–20 months and median overall survival (OS) of 51–57 months can be achieved with the use of imatinib, in metastatic or advanced gastrointestinal stromal tumor (GIST). Sunitinib and regorafenib are approved options for patients progressing on...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Gastrointest Oncol
Autores principales: Ramaswamy, Anant, Pande, Nikhil, Shetty, Omshree, Shetty, Nitin, Gupta, Sudeep, Ostwal, Vikas
Formato: Artigo
Lenguaje:Inglês
Publicado: AME Publishing Company 2016
Materias:
Original Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4963378/
https://ncbi.nlm.nih.gov/pubmed/27563456
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jgo.2016.03.06
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares